A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy

NCT00818181 Phase 2 COMPLETED

This trial is performed to assess safety of a sublingual birch pollen extract.

Details

Lead sponsor	Allergopharma GmbH & Co. KG
Phase	Phase 2
Status	COMPLETED
Enrolment	73
Start date	2008-06
Completion	2010-08

Conditions

• Rhinoconjunctivitis

Interventions

• Biological: AL0206st

Primary outcomes

• number of patients with at least one adverse event — 8 months
  Between Visit 03 and Visit 05 (June 2008 - January 2009)

Countries

Germany